KDR and neoplasm: Sorafenib, a novel multitargeted anticancer drug that targets RAF kinase, c-Kit and RET proto-oncogenes, VEGF receptor (VEGFR), and platelet-derived growth factor receptor (PDGFR), may exert its effects by arresting tumor cell cycles and by exerting anti-vascular effects [94,95].